Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR–TKI benefit in stage IV lung adenocarcinoma - Scorecard - MDSpire

Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR–TKI benefit in stage IV lung adenocarcinoma

  • By

  • Huiru Guo

  • Lingshuang Liu

  • Veronika Lindberg

  • Yingjun Xue

  • Jan P. A. Baak

  • July 10, 2026

  • 0 min

Share

Clinical Scorecard: Prognostic Significance of Baseline Soluble CD25 as a Biomarker for Differential EGFR-TKI Response in Stage IV Lung Adenocarcinoma: Insights from Real-World Evidence

At a Glance

CategoryDetail
ConditionStage IV Lung Adenocarcinoma
Key MechanismsSoluble interleukin-2 receptor (sCD25) reflects IL-2 pathway activation and T-cell regulation.
Target PopulationPatients with newly diagnosed stage IV LUAD, ECOG performance status 0–1, and survival ≥3 months.
Care SettingProspective observational study

Key Highlights

  • Elevated sCD25 (≥441 U/mL) is associated with shorter overall survival (OS).
  • One- and three-year OS rates are significantly lower in high sCD25 patients.
  • sCD25 may help refine EGFR-TKI selection based on differential treatment response.

Guideline-Based Recommendations

Diagnosis

  • Evaluate baseline sCD25 levels in patients with stage IV LUAD.

Management

  • Consider sCD25 levels when selecting EGFR-TKIs for treatment.

Monitoring & Follow-up

  • Monitor sCD25 levels as a potential prognostic biomarker.

Risks

  • High sCD25 levels indicate a higher risk of shorter OS.

Patient & Prescribing Data

133 consecutive patients with newly diagnosed stage IV LUAD.

EGFR-TKI benefit is limited to high sCD25 subgroup.

Clinical Best Practices

  • Incorporate sCD25 measurement in the treatment planning for stage IV LUAD.
  • Use sCD25 as a prognostic tool alongside other biomarkers.

Related Resources & Content

Original Source(s)

Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR–TKI benefit in stage IV lung adenocarcinoma

  • by Huiru Guo, Lingshuang Liu, Veronika Lindberg, Yingjun Xue, Jan P. A. Baak

  • July 10, 2026

Related Content

Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications

The effects of brain radiotherapy combined with immunotherapy and chemotherapy for driver gene-negative non-small-cell lung cancer with brain metastases

Single-cell and spatial omics in non-small cell lung cancer: dissecting metabolic reprogramming and tumor-immune ecosystems for precision pharmacology